LVS Stock Analysis: Las Vegas Sands | NYSE
Resorts & Casinos | NYSE, USA | Market Cap: 23.946m USD | 12M Return: -33.5% | US5178341070 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 244M
EPS Trend: 84.8%
Qual. Beats: -2
Rev. Trend: 93.4%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Las Vegas Sands Corp. (LVS) is a major operator of integrated resorts, with all of its operations concentrated in Macao and Singapore. Its Macao portfolio includes The Venetian Macao, The Londoner Macao, The Parisian Macao, The Plaza Macao and Four Seasons Hotel Macao, and The Sands Macao, while in Singapore it operates Marina Bay Sands. Founded in 1988 and headquartered in Las Vegas, Nevada, the company is classified in the Consumer Discretionary sector under the Casinos & Gaming sub-industry.
LVSs integrated resorts combine gaming with hotels, entertainment venues, retail malls, convention and exhibition facilities, and celebrity chef restaurants, generating revenue across both gaming and non-gaming segments. This integrated resort model is the dominant business structure in Asian gaming markets, allowing operators to capture spending from a broader base of leisure and business travelers rather than gaming customers alone.
Macao is one of the largest gaming markets in the world, and Singapores casino sector operates under a limited-licence framework, with Marina Bay Sands being one of only two licensed integrated resorts in the country.
- Macao mass-market gaming revenue recovery lifts consolidated EBITDA
- Marina Bay Sands Singapore posts record margins on tourism rebound
- China consumer slowdown and travel restrictions pressure Macao visitation
- Capital returns through dividend and buyback program accelerate
| Net Income: 1.64b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 6.08 > 1.0 |
| NWC/Revenue: -5.90% < 20% (prev -4.23%; Δ -1.66% < -1%) |
| CFO/TA 0.18 > 3% & CFO 3.50b > Net Income 1.64b |
| Net Debt (12.6b) to EBITDA (4.46b): 2.82 < 3 |
| Current Ratio: 0.83 > 1.5 & < 3 |
| Outstanding Shares: last quarter (640.0m) vs 12m ago -6.57% < -2% |
| Gross Margin: 49.90% > 18% (prev 49.94%; Δ -0.04% > 0.5%) |
| Asset Turnover: 66.49% > 50% (prev 57.04%; Δ 9.45% > 0%) |
| Interest Coverage Ratio: 3.94 > 6 (EBIT TTM 2.97b / Interest Expense TTM 754.0m) |
| A: -0.04 (Total Current Assets 3.82b - Total Current Liabilities 4.62b) / Total Assets 19.4b |
| B: 0.26 (Retained Earnings 5.01b / Total Assets 19.4b) |
| C: 0.15 (EBIT TTM 2.97b / Avg Total Assets 20.5b) |
| D: -0.02 (Book Value of Equity -344.0m / Total Liabilities 19.5b) |
| Altman-Z'' = 1.53 = BB |
| DSRI: 1.09 (Receivables 664.0m/548.0m, Revenue 13.6b/12.3b) |
| GMI: 1.00 (GM 49.94% / 49.90%) |
| AQI: 0.84 (AQ_t 0.21 / AQ_t-1 0.25) |
| SGI: 1.11 (Revenue 13.6b / 12.3b) |
| TATA: -0.10 (NI 1.64b - CFO 3.50b) / TA 19.4b) |
| Beneish M = -2.98 (Cap -4..+1) = A |
As of November 09, 2026, the stock is trading at USD 40.73 with a total of 7,039,874 shares traded. Over the past week, the price has changed by +11.07%, over one month by +13.09%, over three months by -10.95% and over the past year by -33.46%.
Current recommended Stop Loss: 39.30 (which is 3.5% or 1.3 ATR below the current price).
Las Vegas Sands has received a consensus analysts rating of 4.19. Therefore, it is recommended to buy LVS.
- StrongBuy: 11
- Buy: 3
- Hold: 7
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 49.6 | 21.7% |
P/E Trailing = 15.1516
P/E Forward = 11.325
P/S = 1.7602
P/B = 40.7684
P/EG = 0.9765
Revenue TTM = 13.6b USD
EBIT TTM = 2.97b USD
EBITDA TTM = 4.46b USD
Long Term Debt = 13.9b USD (from longTermDebt, last quarter)
Short Term Debt = 1.57b USD (from shortTermDebt, last quarter)
Debt = 15.4b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.6b USD (calculated: Debt 15.4b - CCE 2.86b)
Enterprise Value = 36.5b USD (23.9b + Debt 15.4b - CCE 2.86b)
Interest Coverage Ratio = 3.94 (Ebit TTM 2.97b / Interest Expense TTM 754.0m)
EV/FCF = 15.12x (Enterprise Value 36.5b / FCF TTM 2.42b)
FCF Yield = 6.61% (FCF TTM 2.42b / Enterprise Value 36.5b)
FCF Margin = 17.76% (FCF TTM 2.42b / Revenue TTM 13.6b)
Net Margin = 12.05% (Net Income TTM 1.64b / Revenue TTM 13.6b)
Gross Margin = 49.90% ((Revenue TTM 13.6b - Cost of Revenue TTM 6.82b) / Revenue TTM)
Gross Margin QoQ = 45.62% (prev 57.23%)
Tobins Q-Ratio = 1.88 (Enterprise Value 36.5b / Total Assets 19.4b)
Interest Expense / Debt = 4.88% (Interest Expense 754.0m / Debt 15.4b)
Taxrate = 10.12% (224.0m / 2.21b)
NOPAT = 2.67b (EBIT 2.97b * (1 - 10.12%))
Current Ratio = 0.83 (Total Current Assets 3.82b / Total Current Liabilities 4.62b)
Debt / Equity = -44.90 (negative equity) (Debt 15.4b / totalStockholderEquity, last quarter -344.0m)
Debt / EBITDA = 2.82 (Net Debt 12.6b / EBITDA 4.46b)
Debt / FCF = 5.21 (Net Debt 12.6b / FCF TTM 2.42b)
Total Stockholder Equity = 756.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 8.01% (Net Income 1.64b / Total Assets 19.4b)
RoE = 216.6% (Net Income TTM 1.64b / Total Stockholder Equity 756.8m)
RoCE = 20.28% (EBIT 2.97b / Capital Employed (Equity 756.8m + L.T.Debt 13.9b))
RoIC = 17.01% (NOPAT 2.67b / Invested Capital 15.7b)
WACC = 6.72% (E(23.9b)/V(39.4b) * Re(8.23%) + D(15.4b)/V(39.4b) * Rd(4.88%) * (1-Tc(0.10)))
Discount Rate = 8.23% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -98.31 | Cagr: -6.31%
[DCF] Terminal Value 77.97% ; FCFF base≈2.00b ; Y1≈2.29b ; Y5≈3.37b
[DCF] Fair Price = 58.84 (EV 50.7b - Net Debt 12.6b = Equity 38.1b / Shares 647.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 84.80 | EPS CAGR: 17.74% | SUE: -1.17 | # QB: -2
Revenue Correlation: 93.41 | Revenue CAGR: 10.40% | SUE: -0.53 | # QB: 0
EPS current Quarter (2027-03-31): EPS=0.76 | Chg30d=-18.80% | Revisions=-25% | Analysts=5
EPS current Year (2026-12-31): EPS=2.81 | Chg30d=-8.80% | Revisions=-50% | GrowthEPS=-6.5% | GrowthRev=+3.5%
EPS next Year (2027-12-31): EPS=3.09 | Chg30d=-11.40% | Revisions=-50% | GrowthEPS=+10.0% | GrowthRev=+3.8%
[Analyst] Revisions Ratio: -70% (up=0, down=7)